Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia (Q83145640)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

chronic myeloid leukemia

1 reference

1 reference

Takeru Nambu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Akinobu Hamada

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Reiko Nakashima

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Misato Yuki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Tatsuya Kawaguchi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Hiroaki Mitsuya

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Hideyuki Saito

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

Biological and Pharmaceutical Bulletin

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

114-119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

19 January 2020

cites work

1 reference

12 December 2020

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

12 December 2020

Interaction of imatinib mesilate with human P-glycoprotein

1 reference

12 December 2020

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

1 reference

12 December 2020

Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions

1 reference

12 December 2020

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment

1 reference

12 December 2020

OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients

1 reference

12 December 2020

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

1 reference

12 December 2020

hOCT 1 and resistance to imatinib

1 reference

12 December 2020

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

1 reference

12 December 2020

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

1 reference

12 December 2020

Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells

1 reference

12 December 2020

Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1

1 reference

12 December 2020

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells

1 reference

12 December 2020

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

12 December 2020

Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

1 reference

12 December 2020

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

12 December 2020

Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).

1 reference

12 December 2020

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

1 reference

12 December 2020

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

12 December 2020

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Interaction of imatinib with human organic ion carriers

1 reference

12 December 2020

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

1 reference

12 December 2020

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

12 December 2020

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

12 December 2020

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

1 reference

12 December 2020

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer

1 reference

12 December 2020

Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia.

1 reference

12 December 2020

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

12 December 2020

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

12 December 2020

A METHOD FOR THE ISOLATION OF HUMAN LYMPHOCYTES.

1 reference

12 December 2020

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

12 December 2020

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

12 December 2020

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

12 December 2020

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells

1 reference

12 December 2020

Identifiers

DOI

10.1248/BPB.34.114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21212528%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference